Parkinson Disease Gastrointestinal Dysfunction Lecture

All About Parkinson's Disease

All About Parkinson's Disease

Get Instant Access

1. Parkinson, J., An Essay on the Shaking Palsy, Whitting-ham and Rowland, London, 1817.

2. Romberg, M. H., Nervous Diseases of Man, Sydenham Society, London, 1853.

3. Charcot, J. M., Lectures on the Diseases of the Nervous System, Vol. 1, New Sydenham Society, London, 1877.

4. Hammond, W. A., A Treatise on Diseases of the Nervous System, Appleton and Company, New York, 1871.

5. Gowers, W. R., Diseases of the Nervous System, P. Blak-iston and Company, Philadelphia, 1888.

6. Eadie, M. J. and Tyrer, J. H., Alimentary disorder in parkinsonism, Aust. Ann. Med., 14, 13, 1965.

Edwards, L. L. et al., Gastrointestinal symptoms in Parkinson's disease, Mov. Disord., 6, 151, 1991. Edwards, L. L. et al., Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology, Neurology, 42, 726, 1992.

Edwards, L. L. et al., Gastrointestinal symptoms in Parkinson's disease: 18 month follow-up study, Mov. Disord. 8, 83, 1993.

Edwards, L. L. et al., Characterization of swallowing and defecation in Parkinson's disease, Am. J. Gastroen-terol., 89, 15, 1994.

Pfeiffer, R. F. and Quigley, E. M. M., Gastrointestinal motility problems in patients with Parkinson's disease: epidemiology, pathophysiology and guidelines for management, CNS Drugs, 11, 435, 1999. Quigley, E. M. M., Gastrointestinal dysfunction in Parkinson's disease, Semin. Neurol., 16, 245, 1996. Quigley, E. M. M., Epidemiology and pathophysiology of gastrointestinal manifestations in Parkinson's disease, in NeuroGastro-enterology, Corazziari, E., Ed., deGruyter, Berlin, 1996, 167.

Pfeiffer, R. F., Gastrointestinal dysfunction in Parkinson's disease, Clin. Neurosci, 5, 136, 1998. Quigley, E. M. M., Gastrointestinal features, in Parkinson's Disease. Diagnosis and Clinical Management, Factor, S. A. and Weiner, W. J., Eds., Demos, New York, 87, 2002.

Pfeiffer, R. F., Gastrointestinal dysfunction in Parkinson's disease, Lancet Neurol., 2, 107, 2003. Wuttge-Hanning, A. and Hannig, C., Radiologic differential diagnosis of neurologically-induced deglutition disorders, Radiologe, 35, 733, 1995. Hunter, P. C. et al., Response of parkinsonian swallowing dysfunction to dopaminergic stimulation, J. Neurol. Neurosurg. Psychiatry, 63, 579, 1997. Miller, A. J., Neurophysiological basis of swallowing, Dysphagia, 1, 91, 1986.

Hamdy, S. et al., Identification of the cerebral loci processing human swallowing with H215O PET activation, J. Neurophysiol., 81, 1917, 1999. Long, J. D. and Orlando, R. C., Anatomy, histology, embryology, and developmental anomalies of the esophagus, in Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 7th ed., Feldman, M., Friedman, L. S., and Sleisenger, M. H., Eds., Chap. 31, Saunders, Philadelphia, 2002.

Clouse, R. E. and Diamant, N. E., Esophageal motor and sensory function and motor disorders of the esophagus, in Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 7th ed., Chap. 32, Feldman, M., Friedman, L.S., and Sleisenger, M.H., Eds., Saunders, Philadelphia, 2002.

Quigley, E. M. M., Gastric motor and sensory function, and motor disorders of the stomach, in Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 7th ed., Chap. 37, Feldman, M., Friedman, L. S., and Sleisenger, M. H., Eds., Saunders, Philadelphia, 2002. Keljo, D. J. and Gariepy C. E., Anatomy, histology, embryology, and developmental anomalies of the small and large intestine, in Sleisenger and Fordtran's Gas trointestinal and Liver Disease, 7th ed., Chap. 84, Feld-man, M., Friedman, L.S., and Sleisenger, M.H., Eds., Saunders, Philadelphia, 2002.

25. Andrews, J. M. and Dent, J., Small intestinal motor physiology, in Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 7th ed., Chap. 85, Feldman, M., Friedman, L.S., and Sleisenger, M.H., Eds., Saunders, Philadelphia, 2002.

26. Cook, I. J. and Brookes, S. J., Motility of the large intestine, in Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 7th ed., Chap. 86, Feldman, M., Friedman, L.S., and Sleisenger, M.H., Eds., Saunders, Philadelphia, 2002.

27. Madoff, R. D., Williams, J. G., and Caushaj, P. F., Fecal incontinence, N. Engl. J. Med., 326, 1002, 1992.

28. Abbott, R. A. et al., Diet, body size and micronutrient status in Parkinson's disease, Eur. J. Clin. Nutr, 46, 879, 1992.

29. Beyer, P. L. et al., Weight change and body composition in patients with Parkinson's disease, J. Am. Diet Assoc., 95, 979, 1995.

30. Chen, H. et al., Weight loss in Parkinson's disease, Ann. Neurol, 53, 676, 2003.

31. Toth, M. J., Fishman, P. S., and Poehlman, E. T., Free-living daily energy expenditure in patients with Parkinson's disease, Neurology, 48, 88, 1997.

32. Davies, K. N., King, D., and Davies, H., A study of the nutritional status of elderly patients with Parkinson's disease, Age Ageing, 23, 142, 1994.

33. Davies, K. N. et al., Intestinal permeability and orocaecal transit time in elderly patients with Parkinson's disease, Postgrad. Med. J, 72, 164, 1996.

34. Markus, H. S., Cox, M., and Tomkins, A. M., Raised energy expenditure in Parkinson's disease and its relationship to muscle rigidity, Clin. Sci., 83, 199, 1992.

35. Kempster, P. A. and Wahlqvist, M. L., Dietary factors in the management of Parkinson's disease, Nutr. Rev., 52, 51, 1994.

36. Gironell, A. et al., Weight gain after functional surgery for Parkinson's disease, Neurologia, 17, 310, 2002.

37. Ondo, W. G. et al., Weight gain following unilateral pallidotomy in Parkinson's disease, Acta Neurol. Scand, 101, 79, 2000.

38. Wang, G. J. et al., Brain dopamine and obesity, Lancet, 357, 354, 2001.

39. Volkow, N. D. et al., "Nonhedonic" food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect, Synapse, 44, 175, 2002.

40. Volkow, N. D. et al., Brain dopamine is associated with eating behaviors in humans, Int. J. Eat. Disord., 33, 136, 2003.

41. Evidente, V. G. H. et al., Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss, Mov. Disord, 16, 924, 2001.

42. Batterham, R. L. et al., Inhibition of food intake in obese subjects by peptide YY3-36, N. Engl. J. Med., 349, 941, 2003.

Korner, J. and Leibel, R. L., To eat or not to eat—how the gut talks to the brain, N. Engl. J. Med, 349, 926, 2003.

Dirks, S. J. et al., The patient with Parkinson's disease, Quintessence Int., 34, 379, 2003. Clifford, T. and Finnerty, J., The dental awareness and needs of a Parkinson's disease population, Gerodontol-ogy, 12, 99, 1995.

Durham, T. M. et al., Management of orofacial manifestations of Parkinson's disease with splint therapy: a case report, Spec. Care Dentist., 13, 155, 1993. Jolly, D. E. et al., Parkinson's disease: a review and recommendations for dental management, Spec. Care Dentist., 9, 74, 1989.

Chiappelli, F. et al., Dental needs of the elderly in the 21st century, Gen. Dent., 50, 358, 2002. Fiske, J. and Hyland, K., Parkinson's disease and oral care, Dent. Update, 27, 58, 2000. Kieser, J. et al., Dental treatment of patients with neurodegenerative disease, N. Z. Dent. J., 95, 130, 1999. Kennedy, M. A. et al., Relationship of oral microflora with oral health status in Parkinson's disease, Spec. Care Dentist., 14, 164, 1994.

Persson, M. et al., Influence of Parkinson's disease on oral health, Acta Odontol. Scand., 50, 37, 1992. Fukayo, S., Dental status in outpatients with Parkinson's disease, Nippon. Eiseigaku Zasshi., 57, 585, 2002. Anastassiadou, V. et al., Evaluating dental status and prosthetic need in relation to medical findings in Greek patients suffering from idiopathic Parkinson's disease, Eur. J. Prosthodont. Restor. Dent., 10, 63, 2002. Clifford, T. J. et al., Burning mouth in Parkinson's disease sufferers, Gerodontology, 15, 73, 1998. Srivastava T. et al., Bruxism as presenting feature of Parkinson's disease, J. Assoc. Physicians India, 50, 457, 2002.

Magee, K. R., Bruxisma related to levodopa therapy, JAMA, 214, 147, 1970.

Sayama, S. et al., Habitual mandibular dislocation in two patients with Parkinson's disease, Rinsho. Shinkeigaku, 39, 849, 1999.

Minagi, S. et al., An appliance for management of TMJ pain as a complication of Parkinson's disease, Cranio, 16, 57, 1998.

Heckmann, S. M., Heckmann, J. G., and Weber, H. P., Clinical outcomes of three Parkinson's disease patients treated with mandibular implant overdentures, Clin. Oral Implants Res., 11, 566, 2000. Ngim, C. H. and Devathasan, G., Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease, Neuroepidemiology, 8, 128, 1989.

Bagheri, H. et al., A study of salivary secretion in Parkinson's disease, Clin. Neuropharmacol., 22, 213, 1999. Bateson, M. C., Gibberd, F. B., and Wilson, R. S. E., Salivary symptoms in Parkinson's disease, Arch. Neurol, 29, 274, 1973.

Eadie, M. J., Gastric secretion in parkinsonism, Aust. Ann. Med, 12, 346, 1963.

65. Marks, L. et al., Drooling in Parkinson's disease: a novel speech and language therapy intervention, Int. J. Lang. Commun. Disord, 36 (Suppl.), 282, 2001.

66. Hyson, H. C., Jog, M. S., and Johnson, A., Sublingual atropine for sialorrhea secondary to parkinsonism. Parkinsonism Relat. Disord, 7 (Suppl.), 194, 2001 (abstract).

67. Bhatia, K. P., Munchau, A., and Brown, P., Botulinum toxin is a useful treatment in excessive drooling of saliva, J. Neurol. Neurosurg. Psychiatry, 67, 697, 1999.

68. Bushara, K. O., Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment—botulinum toxin A injections of the parotid glands, Medical Hypothesis, 48, 337, 1997.

69. Pal, P. K. et al., Botulinum toxin A as a treatment for drooling saliva in PD, Neurology, 54, 244, 2000.

70. Jost, W. H., Treatment of drooling in Parkinson's disease with botulinum toxin, Mov. Disord., 14, 1057, 1999.

71. Friedman, A. and Potulska, A., Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin, Parkinsonism Relat. Disord., 7, 329, 2001.

72. Lipp, A. et al., Treatment of drooling in Parkinson's disease and motorneuron disease with botulinum toxin A, Naunyn Schmiedebergs Arch. Pharmacol., 365 (Suppl. 2), R38, 2002 (abstract).

73. Mancini, F. et al., Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkin-sonism, Mov. Disord., 18, 685, 2003.

74. O'Sullivan, J. D., Bhatia, K. P., and Lees, A. J., Botuli-num toxin A as a treatment for drooling saliva in PD, Neurology, 55, 606, 2000.

75. Mullins, W. M., Gross, C. W., and Moore, J. M., Long-term follow-up of tympanic neurectomy for sialorrhea, Laryngoscope, 89, 1219, 1979.

76. Clarke, C. E. et al., Referral criteria for speech and language therapy assessment of dysphagia caused by idiopathic Parkinson's disease, Acta Neurol. Scand., 97, 27, 1998.

77. Kurihara, K. et al., Dysphagia in Parkinson's disease, Rinsho. Shinkeigaku, 33, 150, 1993.

78. Hartelius, L. and Svensson, P., Speech and swallowing symptoms associated with Parkinson's disease and multiple sclerosis: a survey, Folia. Phoniatr. Logop, 46, 9, 1994.

79. Leopold, N. A. and Kagel, M. C., Prepharyngeal dysphagia in Parkinson's disease, Dysphagia, 11, 14, 1996.

80. Logemann, J. A., Blonsky, E. R., and Boshes, B., Editorial: dysphagia in parkinsonism, J.A.M.A., 231, 69, 1975.

81. Bushmann, M. et al., Swallowing abnormalities and their response to treatment in Parkinson's disease, Neurology, 39, 1309, 1989.

82. Leopold, N. A. and Kagel, M. C., Pharyngo-esophageal dysphagia in Parkinson's disease, Dysphagia, 12, 11, 1997.

83. Fuh, J. L. et al., Swallowing difficulty in Parkinson's disease, Clin. Neurol. Neurosurg., 99, 106, 1997.

Nagaya, M. et al., Videofluorographic study of swallowing in Parkinson's disease, Dysphagia, 13, 95, 1998. Silbiger, M. L., Pikielney, R., and Donner, M. W., Neuromuscular disorders affecting the pharynx. Cineradiography analysis, Invest. Radiol., 2, 442, 1967. Robbins, J. A., Logemann, J. A., and Kirshner, H. S., Swallowing and speech production in Parkinson's disease, Ann. Neurol, 19, 283, 1986. Stroudley, J. and Walsh, M. Radiological assessment dysphagia in Parkinson's disease, Br. J. Radiol., 64, 890, 1991.

Logemann, J., Blonsky, E. R., and Boshes, B., Lingual control in Parkinson's disease, Trans. Am. Neurol. Assoc, 98, 276, 1973.

Blonsky, E. R. et al., Comparison of speech and swallowing function in patients with tremor disorders and in normal geriatric patients: a cinefluorographic, J. Gerontol, 30, 299, 1975.

Ali, G.N. et al., Mechanisms of oral-pharyngeal dysphagia in patients with Parkinson's disease, Gastroenterology, 110, 383, 1996.

Mari, F. et al., Poor predictive value of clinical measures of dysphagia versus aspiration risk in parkinsonian patients, Mov. Disord., 12 (Suppl. 1), 135, 1997. Bird, M. R. et al., Asymptomatic swallowing disorders in elderly patients with Parkinson's disease: a description of findings on clinical examination and videofluo-roscopy in sixteen patients, Age Ageing, 23, 251, 1994. Byrne, K. G., Pfeiffer, R. F., and Quigley, E. M. M., Gastrointestinal dysfunction in Parkinson's disease: a report of clinical experience at a single center, J. Clin. Gastroenterol., 19, 11, 1994.

Eadie, M. J. and Tyrer, J. H., Radiological abnormalities of the upper part of the alimentary tract in parkinsonism, Aust. Ann. Med., 14, 23, 1965.

Gibberd, F. B. et al., Oesophageal dilation in Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 37, 938, 1974. Bassotti, G. et al., Esophageal manometric abnormalities in Parkinson's disease, Dysphagia, 13, 28, 1998. Castell, J. A. et al., Manometric abnormalities of the oesophagus in patients with Parkinson's disease, Neu-rogastroenterol Motil, 13, 361, 2001. Penner, A. and Druckerman, L. J., Segmental spasms of the esophagus and their relation to parkinsonism, Am. J. Dig. Dis, 9, 282, 1942.

Johnston, B. T. et al., Repetitive proximal esophageal contractions: a new manometric finding and a possible further link between Parkinson's disease and achalasia, Dysphagia, 16, 186, 2001.

Cotzias, G. C., Papavasiliou, P. S., and Gellene, R., Modification of parkinsonism—chronic treatment with L-dopa, N. Engl. J. Med. 280, 337, 1969. Paulson, G. R. and Tafrate, R. H., Some minor aspects of parkinsonism, especially pulmonary function, Neurology, 20, 14, 1970.

Nowack, W. J., Hatelid, J. M., and Sohn, R. S., Dysph-agia in parkinsonism, Arch. Neurol, 34, 320, 1977. Leiberman, A.N. et al., Dysphagia in Parkinson's disease, Am. J. Gastroenterol., 74, 157, 1980.

104. Tison, F. et al., Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease, Mov. Disord, 11, 729, 1996.

105. Bramble, M. G., Cunliffe, J., and Dellipani, A. W., Evidence for a change in neurotransmitter affecting oesophageal motility in Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 41, 709, 1978.

106. Restivo, D. A., Palmeri, A., and Machese-Ragona, R., Botulinum toxin for cricopharyngeal dysfunction in Parkinson's disease, N. Engl. J. Med., 346, 1174, 2002.

107. Born, L. J. et al., Cricopharyngeal dysfunction in Parkinson's disease: role in dysphagia and response to myotomy, Mov. Disord., 11, 53, 1996.

108. Wang, S. J. et al., Dysphagia in Parkinson's disease. Assessment by solid phase radionuclide scintigraphy, Clin. Nucl. Med, 19, 405, 1994.

109. Kempster, P. A. et al., Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine, Mov. Disord., 4, 47, 1989.

110. Bortolotti, M. et al., Effects of sildenafil on esophageal motility of patients with idiopathic achalasia, Gastroen-terology, 118, 253, 2000.

111. Kellner, H. et al., Reversible esophageal dysfunction as a side effect of levodopa, Bildgebung, 63, 48, 1996.

112. Luman, W. et al., Percutaneous endoscopic gastros-tomy—indications and outcome of our experience at the Singapore General Hospital, Singapore Med. J., 42, 460, 2001.

113. Evans, M. A. et al., Gastric emptying rate in the elderly: implications for drug therapy, J. Am. Geriatr. Soc., 29, 201, 1981.

114. Sulla, M. et al., Gastric emptying time and gastric motility in patients with untreated Parkinson's disease, Mov. Disord., 11 (Suppl. 1), 167, 1996 (abstract).

115. Hardoff, R. et al., Gastric emptying time and gastric motility in patients with Parkinson's disease, Mov. Dis-ord, 16, 1041, 2001.

116. Djaldetti, R. et al., Gastric emptying in Parkinson's disease: patients with and without response fluctuations, Neurology, 46, 1051, 1996.

117. Krygowska-Wajs, A. et al., Gastric electromechanical dysfunction in Parkinson's disease, Funct. Neurol, 15, 41, 2000.

118. Soykan, I. et al., Gastric myoelectrical activity in patients with Parkinson's disease: evidence of a primary gastric abnormality, Dig. Dis. Sci, 44, 927, 1999.

119. Wade, D. N., Mearrick, P. T., and Morris, J., Active transport of L-dopa in the intestine, Nature, 242, 463, 1973.

120. Sasahara, K. et al., Dosage from design for improvement of bioavailability of levodopa: absorption and metabolism of levodopa in intestinal segment of dogs, J. Pharm. Sci., 70, 1157, 1981.

121. Nutt, J. G. and Fellman, J. H., Pharmacokinetics of levodopa, Clin. Neuropharmacol., 7, 35, 1984.

122. Valenzuela, J. E., Dopamine as a possible neurotrans-mitter in gastric relaxation, Gastroenterology, 71, 1019, 1976.

Berkowitz, D. M. and McCallum, R. W., Interaction of levodopa and metoclopramide on gastric emptying, Clin. Pharmacol. Ther., 27, 414, 1980. Soykan, I. et al., Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease, Mov. Disord, 12, 952, 1997.

Barone, J. A., Domperidone: a peripherally acting dopamine2-receptor antagonist, Ann. Pharmacother., 33, 429, 1999.

Wiseman, L. R. and Faulds, D., Cisapride, An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders, Drugs, 47, 116, 1994.

Boivin, M. A., Carey, M. C., and Levy, H., Erythromycin accelerates gastric emptying in a dose-response manner in healthy subjects, Pharmacotherapy, 23, 5 , 2003. Sturm, A. et al., Prokinetics in patients with gastropare-sis: a systematic analysis, Digestion, 60, 422, 1999. Syed, N. et al., Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease, Mov. Disord., 13, 336, 1998. Vaamonde, J., Luquin, M. R., and Obeso, J., Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients, Brain, 114, 604, 1991.

Stibe, C. M. et al., Subcutaneous apomorphine in parkinsonian on-off oscillations, Lancet, 1, 403, 1988. Behrens, S. and Sommerville, K., Non-oral drug delivery in Parkinson's disease: a summary from the symposium at the 7th International Congress of Parkinson's Disease and Movement Disorders. November 10-14, 2002, Miami, FL, U.S.A., Expert Opin. Pharmacother., 4, 595, 2003.

McCallum, R. W. and George, S. J., Gastric dysmotility and gastroparesis, Curr. Treat. Options Gastroenterol., 4, 179, 2001.

Bozeman, T. et al., Small intestinal manometry in Parkinson's disease, Gastroenterology, 99, 1202, 1990 (abstract).

Lewitan, A., Nathanson, L., and Slade, W. R., Megaco-lon and dilatation of the small bowel in parkinsonism, Gastroenterology, 17, 367, 1952. Eaker, E.Y. et al., Chronic alterations in jejunal myo-electric activity in rats due to MPTP, Am. J. Physiol., 253, G809, 1987.

Emmanuel, A. V. et al., Prucalopride, a systemic enter-okinetic, for the treatment of constipation, Aliment. Pharmacol. Ther, 16, 1347, 2002. Stark, M. E., Challenging problems presenting as constipation, Am. J. Gastroenterol., 94, 567, 1999. Schwab, R. S. and England, A. C., Parkinson's disease, J. Chron. Dis., 8, 488, 1958.

Pallis, C. A., Parkinsonism: natural history and clinical features, B.M.J, 3, 683, 1971.

Siddiqui, M. F. et al., Autonomic dysfunction in Parkinson's disease: a comprehensive symptom survey, Parkinsonism Relat. Disord, 8, 277, 2002. Jost, W. H. and Schimrigk, K., Constipation in Parkinson's disease, Klin. Wochenschr., 69, 906, 1991.

143. Jost, W. H. and Schimrigk, K., The effect of cisapride on delayed colon transit time in patients with idiopathic Parkinson's disease, Wien Klin. Wochenschr., 106, 673, 1994.

144. Sakakibara, R. et al., Colonic transit time and rectoanal videomanometry in Parkinson's disease, J. Neurol. Neu-rosurg. Psychiatry, 74, 268, 2003.

145. Sakakibara, R. et al., Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease, Auton. Neurosci, 92, 76, 2001.

146. Jost, W. H. and Schrank, B., Defecatory disorders in de novo parkinsonians—colonic transit and electromyo-gram of the external anal sphincter, Wien Klin. Wochenschr., 110, 535, 1998.

147. Ashraf, W. et al., Constipation in Parkinson's disease: objective assessment and response to psyllium, Mov. Disord., 12, 946, 1997.

148. Abbott, R. D. et al., Frequency of bowel movements and the future risk of Parkinson's disease, Neurology, 57, 456, 2001.

149. Bueno, L. et al., Involvement of central dopamine and D1 receptors in stress-induced colonic motor alterations in rats, Brain Res. Bull., 29, 135, 1992.

150. Ding, Y. Q. et al., Localization of Barrington's nucleus in the pontine dorsolateral tegmentum of the rabbit, J. Hirnforsch, 39, 375, 1999.

151. Pavcovich, L. A. et al., Novel role for the pontine micturition center, Barrington's nucleus: evidence for coordination of colonic and forebrain activity, Brain Res., 784, 355, 1998.

152. Valentino, R. J., Miselis, R. R., and Pavcovich, L. A., Pontine regulation of pelvic viscera: pharmacological target for pelvic visceral dysfunctions, Trends Pharmacol. Sci., 20, 253, 1999.

153. Vizzard, M. A., Brisson, M., and de Groat, W. C., Transneuronal labeling of neurons in the adult rat central nervous system following inoculation of pseudorabies virus into the colon, Cell Tissue Res., 299, 9, 2000.

154. Kupsky, W. J. et al., Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells, Neurology, 37, 1253, 1987.

155. Wakabayashi, K. et al., Parkinson's disease: an immu-nohistochemical study of Lewy-body containing neurons in the enteric nervous system, Acta Neuropathol, 79, 581, 1990.

156. Wakabayashi, K. et al., Lewy bodies in the visceral autonomic nervous system in Parkinson's disease, in Parkinson's Disease. From Basic Research to Treatment (Advances in Neurology, Vol. 60), Narabayashi, H. et al., Eds., Raven Press, New York, 1993, 609.

157. Singaram, C. et al., Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation, Lancet, 346, 861, 1995.

158. Zhao, R. H. et al., Reduced expression of serotonin receptor(s) in the left colon of patients with colonic inertia, Dis. Colon Rectum, 46, 81, 2003.

159. Lyford, G. L. et al., Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation, Gut, 51, 496, 2002.

Jain, D. et al., Role of interstitial cells of Cajal in motil-ity disorders of the bowel, Am. J. Gastroenterol., 98, 618, 2003.

Wiesel, P. H., Norton, C., and Brazzelli, M., Management of faecal incontinence and constipation in adults with central neurological diseases, Cochrane Database Syst. Rev, 4, CD002115, 2001.

Müller-Lissner, S. A., Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta-analy-sis, B.M.J, 296, 615, 1988.

Corazziari, E. and Badiali, D., Management of lower gastrointestinal tract dysfunction, Semin. Neurol, 16, 289, 1996.

Astarloa, R. et al., Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson's disease, Clin. Neuropharmacol., 15, 375, 1992. Lederle, F. A. et al., Cost-effective treatment of constipation in the elderly: a randomized double-blind comparison of sorbitol and lactulose, Am. J. Med., 89, 597, 1990.

Corazziari, E. et al., Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation, Dig. Dis. Sci., 41, 1636, 1996.

Eichorn, T. E. and Oertel, W. H., Macrogol 3350/elec-trolyte improves constipation in Parkinson's disease and multiple system atrophy, Mov. Disord., 16, 1176, 2001. Jost, W. H. and Schimrigk, K., Cisapride treatment of constipation in Parkinson's disease, Mov. Disord., 8, 339, 1993.

Jost, W. H. and Schimrigk, K., Long-term results with cisapride in Parkinson's disease, Mov. Disord, 12, 423, 1997.

Coremans, G. et al., Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial, Digestion, 67, 82, 2003. Sadjadpour, K., Pyridostigmine bromide and constipation in Parkinson's disease, J.A.M.A, 249, 1148, 1983. Koornstra, J. J. et al., Neostigmine treatment of acute pseudo-obstruction of colon (Ogilvie syndrome), Ned. Tijdschr. Geneeskd., 145, 586, 2001. Pfeiffer, R. F. et al., Effect of NT-3 on bowel function in Parkinson's disease, Mov. Disord, 17, S223, 2002 (abstract).

Roarty, T. P. et al., Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial, Aliment. Pharmacol. Ther, 11, 1059, 1007.

175. Sandyk, R. and Gillman, M. A., Colchicine ameliorates constipation in Parkinson's disease, J. R. Soc. Med., 77, 1066, 1984.

176. Caplan, L. H. et al., Megacolon and volvulus in Parkinson's disease, Radiology, 85, 73, 1965.

177. Rosenthal, M. J. and Marshall, C. E., Sigmoid volvulus in association with parkinsonism. Report of four cases, J. Am. Geriatr. Soc., 35, 683, 1987.

178. Bassotti, G. et al., Manometric investigation of anorectal function in early and late stage Parkinson's disease, J. Neurol. Neurosurg. Psychiatry, 68, 768, 2000.

179. Stocchi, F. et al., Anorectal function in multiple system atrophy and Parkinson's disease, Mov. Disord, 15, 71, 2000.

180. Ashraf, W. et al., Anorectal function in fluctuating (on-off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography, Mov. Dis-ord., 10, 650, 1995.

181. Normand, M. M. et al., Simultaneous electromyography and manometry of the anal sphincters in parkinsonian patients: technical considerations, Muscle Nerve, 19, 110, 1996.

182. Mathers, S. E. et al., Constipation and paradoxical pub-orectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon? J. Neurol. Neurosurg. Psychiatry, 51, 1503, 1988.

183. Mathers, S. E. et al., Anal sphincter dysfunction in Parkinson's disease, Arch. Neurol., 46, 1061, 1989.

184. Ashraf, W., Pfeiffer, R. F., and Quigley, E. M. M., Anorectal manometry in the assessment of anorectal function in Parkinson's disease: a comparison with chronic idiopathic constipation, Mov. Disord., 9, 655, 1994.

185. Edwards, L. L. et al., Defecatory function in Parkinson's disease: response to apomorphine, Ann. Neurol., 33, 490, 1993.

186. Albanese, A. et al., Severe constipation in Parkinson's disease relieved by botulinum toxin, Mov. Disord., 12, 764, 1997.

187. Albanese, A. et al., Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A, Am. J. Gastroenterol., 98, 1439, 2003.

188. Jost, W. H. et al., Perianal thrombosis following injection therapy into the external anal sphincter using bot-ulinum toxin, Dis. Colon Rectum, 38, 781, 1995.

Was this article helpful?

0 0
Constipation Prescription

Constipation Prescription

Did you ever think feeling angry and irritable could be a symptom of constipation? A horrible fullness and pressing sharp pains against the bladders can’t help but affect your mood. Sometimes you just want everyone to leave you alone and sleep to escape the pain. It is virtually impossible to be constipated and keep a sunny disposition. Follow the steps in this guide to alleviate constipation and lead a happier healthy life.

Get My Free Ebook


Post a comment